Featuring a slide presentation and related discussion from Dr Bijal Shah, including the following topics:
- Historical approaches to managing acute lymphoblastic leukemia, their limitations and present approaches to treatment (0:00)
- Mechanistic approach underlying blinatumomab; key clinical trial data and their implications (7:29)
- Mechanistic approaches underlying surovatamig and MK-1045; dosing and administration strategies with various bispecific T-cell engagers (23:27)
- Key clinical trial data with surovatamig; implications for practice (32:38)
- Key clinical trial data with MK-1045; implications for practice (39:02)
- Synthesizing and comparing data across subcutaneous blinatumomab, surovatamig and MK-1045 (42:36)